Bausch Health Companies Inc. Reports Revenue Growth Amidst Net Losses in Q4 and Full-Year 2023 [Yahoo! Finance]
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Yahoo! Finance
Net Loss : GAAP Net Loss Attributable to BHC was $39 million for Q4 and $592 million for the full year. Adjusted EBITDA : Q4 Adjusted EBITDA rose by 6% to $869 million, while full-year Adjusted EBITDA was stable at $3.0 billion. Segment Growth : Notable full-year revenue growth in Salix, International, Solta, and Bausch + Lomb segments. Research and Development : Significant progress in key R&D initiatives, including FDA approval for CABTREOTM and commercial launch plans for new products. Cash Flow : Cash from operating activities was $390 million in Q4 and $1,032 million for the full year. 2024 Outlook : BHC updates its full-year revenue and Adjusted EBITDA guidance, reflecting continued growth expectations. Warning! GuruFocus has detected 4 Warning Signs with BHC. On February 22, 2024, Bausch Health Companies Inc ( NYSE:BHC ) released its 8-K filing , detailing its financial performance for the fourth quarter and full year of 2023. BHC, a global company specializing i
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry EyesBusiness Wire
- Bausch + Lomb Co. (NYSE: BLCO) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $18.00. They now have an "outperform" rating on the stock.MarketBeat
- Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs [Yahoo! Finance]Yahoo! Finance
BLCO
Earnings
- 2/21/24 - Beat
BLCO
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/2/24 - Form 4
- BLCO's page on the SEC website